Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19721598 | 1.00 | REN (0.79) | REN | |
| SCHEMBL1943243 | 1.00 | REN (0.79) | REN | |
| SCHEMBL1940656 | 1.00 | REN (0.79) | REN | |
| SCHEMBL1940655 | 1.00 | REN (0.79) | REN | |
| SCHEMBL799737 | 1.00 | REN (0.79) | REN | |
| SCHEMBL12574618 | 1.00 | REN (0.79) | REN | |
| SCHEMBL8283796 | 0.94 | REN (0.70) | REN | |
| SCHEMBL20017205 | 0.91 | REN (0.67) | REN | |
| SCHEMBL7545740 | 0.91 | REN (0.82) | REN | |
| SCHEMBL14190816 | 0.91 | REN (0.82) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908919-B2 | Cyclic apelin derivatives for the treatment of heart failure | NOVARTIS AG (CH) | 2018-03-06 | — | — | US | disclosed |
| US-20160159871-A1 | CYCLIC APELIN DERIVATIVES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159871-A1 | CYCLIC APELIN DERIVATIVES FOR THE TREATMENT OF HEART FAILURE | APLNR, ACKR3, NPBWR1 | REN 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.